Kirkland & Ellis advised Baxter International in the acquisition of SuppreMol, a biopharmaceutical company based in Martinsried, Germany, for €200 million (approximately $225 million). SuppreMol is a privately held company developing treatment options for autoimmune and allergic diseases. More information on the transaction is available here. The Kirkland team included corporate partners Scott Falk, Björn Holland and Nicole Schlatter, tax partners Keith Villmow and Roderic Pagel, intellectual property partner Neil Hirshman, and associates Melanie Harmon and Dirk Kramer.